Cargando…

Hypoxia-inducible factor-1 alpha as a therapeutic target for primary effusion lymphoma

Primary effusion lymphoma (PEL) is an aggressive B-cell lymphoma with poor prognosis caused by Kaposi’s sarcoma-associated herpesvirus (KSHV). Previous studies have revealed that HIF-1α, which mediates much of the cellular response to hypoxia, plays an important role in life cycle of KSHV. KSHV infe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shrestha, Prabha, Davis, David A., Veeranna, Ravindra P., Carey, Robert F., Viollet, Coralie, Yarchoan, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619862/ https://www.ncbi.nlm.nih.gov/pubmed/28922425 http://dx.doi.org/10.1371/journal.ppat.1006628

Ejemplares similares

Characterization of the Activation of Protein Tyrosine Phosphatase, Receptor-Type, Z Polypeptide 1 (PTPRZ1) by Hypoxia Inducible Factor-2 Alpha
por: Wang, Victoria, et al.
Publicado: (2010)

Induction of KSHV latency-associated nuclear antigen (LANA) by hypoxia and hypoxia-inducible factors (HIF)
por: Veeranna, Ravindra P, et al.
Publicado: (2012)

Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2
por: Shrestha, Prabha, et al.
Publicado: (2021)

Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease
por: Shrestha, Prabha, et al.
Publicado: (2023)

Mechanism and therapeutic implications of pomalidomide-induced immune surface marker upregulation in EBV-positive lymphomas
por: Jaeger, Hannah K., et al.
Publicado: (2023)

RNA Sequencing Reveals that Kaposi Sarcoma-Associated Herpesvirus Infection Mimics Hypoxia Gene Expression Signature
por: Viollet, Coralie, et al.
Publicado: (2017)

Next-Generation Sequencing Analysis Reveals Differential Expression Profiles of MiRNA-mRNA Target Pairs in KSHV-Infected Cells
por: Viollet, Coralie, et al.
Publicado: (2015)

Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma
por: Dai, Lu, et al.
Publicado: (2017)

Current Concepts in Primary Effusion Lymphoma and Other Effusion-Based Lymphomas
por: Kim, Yoonjung, et al.
Publicado: (2014)

Regulation of Retroviral and SARS-CoV-2 Protease Dimerization and Activity through Reversible Oxidation
por: Davis, David A., et al.
Publicado: (2022)

Primary Effusion Lymphoma Presenting As Parapneumonic Pleural Effusion
por: Gujarathi, Rahul, et al.
Publicado: (2022)

Indolent primary effusion lymphoma
por: Nagrale, Vidya, et al.
Publicado: (2020)

Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma
por: Nayar, Utthara, et al.
Publicado: (2010)

Targeting of Prosurvival Pathways as Therapeutic Approaches against Primary Effusion Lymphomas: Past, Present, and Future
por: Granato, Marisa, et al.
Publicado: (2015)

Kaposi sarcoma herpesvirus viral load as a biomarker for leptomeningeal involvement by primary effusion lymphoma
por: Lurain, Kathryn, et al.
Publicado: (2022)

Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma
por: Burbelo, Peter D, et al.
Publicado: (2010)

Diagnostic significance of adenosine deaminase in pleural effusate for primary effusion lymphoma–like lymphoma
por: Nakako, Soichiro, et al.
Publicado: (2020)

Primary Effusion Lymphoma without an Effusion: A Rare Case of Solid Extracavitary Variant of Primary Effusion Lymphoma in an HIV-Positive Patient
por: Hashmi, Hamza, et al.
Publicado: (2018)

Primary effusion lymphoma: current perspectives
por: Narkhede, Mayur, et al.
Publicado: (2018)

CDK4/6 inhibitors sensitize gammaherpesvirus-infected tumor cells to T-cell killing by enhancing expression of immune surface molecules
por: Wu, Yiquan, et al.
Publicado: (2022)

Identification of Caspase Cleavage Sites in KSHV Latency-Associated Nuclear Antigen and Their Effects on Caspase-Related Host Defense Responses
por: Davis, David A., et al.
Publicado: (2015)

Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma
por: Gasperini, Paola, et al.
Publicado: (2009)

Primary Effusion Lymphoma: A Clinicopathologic Perspective
por: Gathers, Diamone A., et al.
Publicado: (2022)

Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma
por: Borsi, Enrica, et al.
Publicado: (2014)

Primary Effusion Lymphoma: A Rare and Challenging Diagnosis for Recurrent Pleural Effusion
por: Pereira, Letícia Jacome, et al.
Publicado: (2023)

Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors
por: Tolani, Bhairavi, et al.
Publicado: (2013)

A unique case of primary effusion lymphoma‐like lymphoma showing disappearance and recurrence of the body cavity effusion
por: Koeda, Chikahiko, et al.
Publicado: (2017)

Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma
por: Quentmeier, Hilmar, et al.
Publicado: (2022)

Spontaneous regression of dasatinib-related primary effusion lymphoma-like lymphoma
por: Hayashino, Kenta, et al.
Publicado: (2022)

A Case of Human Herpes Virus-8 Unrelated Primary Effusion Lymphoma-Like Lymphoma Presented as Pleural Effusion
por: Kim, Kyung Ho, et al.
Publicado: (2012)

Primary Effusion Lymphoma-like Lymphoma Mimicking Tuberculous Pleural Effusion: Three Case Reports and a Literature Review
por: Hayashino, Kenta, et al.
Publicado: (2022)

Primary effusion lymphoma involving three body cavities
por: Brimo, Fadi, et al.
Publicado: (2009)

Primary Effusion Lymphoma: An Untrivial Differential Diagnosis for Ascites
por: Ceran, Funda, et al.
Publicado: (2009)

MALT1 protease activity in primary effusion lymphoma
por: Juilland, Mélanie, et al.
Publicado: (2017)

Rapamycin reduces primary effusion lymphoma progression by targeting VEGF production and VEGF responses
por: Gasperini, P, et al.
Publicado: (2009)

Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma
por: Caro-Vegas, Carolina, et al.
Publicado: (2019)

Productive herpesvirus lytic replication in primary effusion lymphoma cells requires S-phase entry
por: Hollingworth, Robert, et al.
Publicado: (2020)

Rare case of primary pleural lymphoma presenting with pleural effusion
por: Sun, Mei‐ling, et al.
Publicado: (2015)

Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy?
por: Jessamy, Kegan, et al.
Publicado: (2016)

Primary Effusion Lymphoma: A Clinicopathological Study of 70 Cases
por: Hu, Zhihong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_phibmd9tsha3gv5131r9vtqpvp